Last reviewed · How we verify
Transarterial Chemoembolization
Transarterial Chemoembolization involves delivering chemotherapy directly to a tumor via the bloodstream, followed by embolization to block blood flow to the tumor.
Transarterial Chemoembolization involves delivering chemotherapy directly to a tumor via the bloodstream, followed by embolization to block blood flow to the tumor. Used for Hepatocellular carcinoma.
At a glance
| Generic name | Transarterial Chemoembolization |
|---|---|
| Also known as | TACE |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach allows for high concentrations of chemotherapy to be delivered directly to the tumor, while minimizing systemic side effects. The embolization component helps to reduce blood flow to the tumor, further increasing the effectiveness of the chemotherapy.
Approved indications
- Hepatocellular carcinoma
Common side effects
- Hepatotoxicity
- Pain
- Fever
Key clinical trials
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (PHASE2)
- GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring
- IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (PHASE2)
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer (PHASE1)
- A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (NA)
- Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma (PHASE2)
- Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: